Close Menu

NEW YORK – Immune prognostic tools developer PredictImmune announced Monday an exclusive partnership for diagnostic company Theradiag to promote, license, and distribute the PredictSure IBD test in French-speaking countries in Europe and Africa.

France-based Theradiag, which specializes in in vitro diagnostics and theranostics for autoimmune disease, will lead commercialization in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries in northwest Africa.

Other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.